SlideShare a Scribd company logo
WAIST-TO-TALLNESS RATIO AS A MARKER OF
                                          CARDIOVASCULAR DISEASE RISK IN PRIMARY
                                                       PREVENTION.
ABCs of Health




                                              Robert C. Lowe, MA1, Debbie Zimmerman, MBA1, and Philip Chen, MD, PhD2

                                       1Polk   County School Board, Winter Haven, Florida and 2Cognoscenti Health Institute,
                                                                         Orlando, Florida.


                                      Introduction                                                                                                  Results

   Recent research has suggested that Waist-To-Tallness Ratio (WTR) has greater               There were no significant differences between males and females for AGE, SMOKE, or PA
                                                                                                                                -




   specificity and sensitivity for overall-cardiovascular disease (CVD) risk than either      (P > 0.05). Females were more likely to have a family history of CVD and DM (P < 0.05).
   body mass index (BMI) or waist circumference (WC). Schneider, et al. (2005) recently       Both male and female WC (100.6 ± 14 cm and 86.2 ± 16 cm, respectively) was below
   reported a cut-off value for WTR of 0.53 for women and 0.55 for men.                       current cut-points. Females had increased %BF compared to males (35.2 ± 7% vs. 27.0
                                                                                              ± 7%). Males had greater BMI (30.2 ± 7 vs. 29.0 ± 5), SBP (131 ± 15 mmHg vs. 124 ±
                                                                                              17 mmHg) and DBP (83 ± 10 mmHg vs. 79 ± 10 mmHg) compared to females (all P <
                                                                                              0.05). Male WTR (0.57; P < 0.05) was greater than cut-point and female WTR (0.53; P =
                                        Purpose                                               0.37) equaled cut point



   To determine whether WTR is a useful marker of CVD risk in primary prevention.              Table 1. Bivariate correlations between Waist to Height Ratio and selected variables.


                                                                                                                                          Heart
                                                                                                                               Smoking    Disease    Diabetes   Physical           Systolic Diastolic Body
                                                                                                             Age      Gender   History    History    History    Activity Weight    BP       BP        Fat     BMI
                                                                                               Pearson
                                       Methods                                                 Correlation   0.19**   0.14**   0.06       0.06       0.09**     -0.13**   0.81**   0.37**   0.31**   0.64**   0.88**

                                                                                               p value       0.000    0.000    0.060      0.069      0.007      0.000     0.000    0.000    0.000    0.000    0.000

                                                                                               subjects      887      887      885        875        862        877       887      884      881      613      872
   Adults (n = 887; AGE = 46.6 ± 11yrs) completed a smoking (SMOKE), heart disease
   (CVD), diabetes (DM) and physical activity (PA) survey at a wellness screening.
   Height, weight, WC, systolic blood pressure (SBP), diastolic blood pressure (DBP), and           **Correlation is significant at the 0.01 level (2-tailed)
   percent body fat (%BF) were measured; BMI and WTR were calculated. Differences
   between genders for CVD risk were explored by one-way ANOVA; differences between
   gender cut-points and WTR were compared by one sample t-test; significance was set                                                         Conclusions
   at P < 0.05..


                                                                                            Both males and females were at increased risk for CVD based on WTR cut-points suggested by
                                                                                            Schneider, et al. (2005) despite WC being below current cut-points. The greater WTR cut-point
                                                                                            in males was associated with increased BMI, SBP, and DBP compared to females. These results
                                                                                            suggest WTR alone may not adequately predict overall CVD risk in adults. In addition, it may be
                            For further information please contact:                         useful to consider gender differences when designing primary prevention interventions to
                                 Robert Lowe, M.A., FAACVPR                                 reduce overall risk for CVD.
                                    robert.lowe@polk-fl.net

More Related Content

Similar to AACVPR 2006

Obesity paradox
Obesity paradoxObesity paradox
07 abdominal obesity_and_association_with.1
07   abdominal obesity_and_association_with.107   abdominal obesity_and_association_with.1
07 abdominal obesity_and_association_with.1
Chistian Laguado
 
07 abdominal obesity_and_association_with.1
07   abdominal obesity_and_association_with.107   abdominal obesity_and_association_with.1
07 abdominal obesity_and_association_with.1
Chistian Laguado
 
Obesity and Cardiovascular Disease
Obesity and Cardiovascular Disease Obesity and Cardiovascular Disease
Obesity and Cardiovascular Disease
magdy elmasry
 
Abdominal Obesity or Visceral Adiposity In HIV patients
Abdominal Obesity or Visceral Adiposity In HIV patientsAbdominal Obesity or Visceral Adiposity In HIV patients
Abdominal Obesity or Visceral Adiposity In HIV patients
UC San Diego AntiViral Research Center
 
COMPARISON OF RISK FACTORS IN YOUNG ADULTS WITH OLDER ADULT PATIENTS WITH REC...
COMPARISON OF RISK FACTORS IN YOUNG ADULTS WITH OLDER ADULT PATIENTS WITH REC...COMPARISON OF RISK FACTORS IN YOUNG ADULTS WITH OLDER ADULT PATIENTS WITH REC...
COMPARISON OF RISK FACTORS IN YOUNG ADULTS WITH OLDER ADULT PATIENTS WITH REC...
DrSajadAhmedBadvi
 
Jennifer Tremmel - Sex Differences In Cardiovascular Disease
Jennifer Tremmel - Sex Differences In Cardiovascular DiseaseJennifer Tremmel - Sex Differences In Cardiovascular Disease
Jennifer Tremmel - Sex Differences In Cardiovascular Disease
Clayman Institute
 
How Should One Decide Whom to Treat for Hypertension? How Should One Decide...
How Should One Decide Whom to Treat for Hypertension? 	 How Should One Decide...How Should One Decide Whom to Treat for Hypertension? 	 How Should One Decide...
How Should One Decide Whom to Treat for Hypertension? How Should One Decide...
MedicineAndHealthUSA
 
Lifestyle and chronic diseases - Dr.Ravi Andrews
Lifestyle and chronic diseases  - Dr.Ravi Andrews Lifestyle and chronic diseases  - Dr.Ravi Andrews
Lifestyle and chronic diseases - Dr.Ravi Andrews
Apollo Hospitals
 
Managing co morbidities of inflammatory arthritis
Managing co morbidities of inflammatory arthritisManaging co morbidities of inflammatory arthritis
Managing co morbidities of inflammatory arthritis
Ministry of Health
 
BODY FAT DEPOSITION AND RISK FACTORS OF CARDIOVASCULAR DISEASES IN MEN
BODY FAT DEPOSITION AND RISK FACTORS OF CARDIOVASCULAR DISEASES IN MENBODY FAT DEPOSITION AND RISK FACTORS OF CARDIOVASCULAR DISEASES IN MEN
BODY FAT DEPOSITION AND RISK FACTORS OF CARDIOVASCULAR DISEASES IN MEN
Prof William Alves Lima
 
Obesity and heart disease
Obesity and heart diseaseObesity and heart disease
Obesity and heart disease
Prateek Singh
 
Diet, obesity, lifestyle and cancer prevention: epidemiologic perspectives
Diet, obesity, lifestyle and cancer prevention: epidemiologic perspectives Diet, obesity, lifestyle and cancer prevention: epidemiologic perspectives
Diet, obesity, lifestyle and cancer prevention: epidemiologic perspectives
Graham Colditz
 
Newsletter July07
Newsletter July07Newsletter July07
Newsletter July07
robwear
 
Riesgo Cardiovascular en el paciente VIH
Riesgo Cardiovascular en el paciente VIHRiesgo Cardiovascular en el paciente VIH
Riesgo Cardiovascular en el paciente VIH
Medint81
 
Obesity and risk factor
Obesity and risk factorObesity and risk factor
Obesity and risk factor
helix1661
 
AliceTang
AliceTangAliceTang
AliceTang
nacsconf
 
HIV and Nutrition Presentation
HIV and Nutrition PresentationHIV and Nutrition Presentation
HIV and Nutrition Presentation
Gastrodiet
 
Heart health for PLHIV: some directions
Heart health for PLHIV:  some directionsHeart health for PLHIV:  some directions
Heart health for PLHIV: some directions
Australian Federation of AIDS Organisations
 
Hypertension: New Concepts, Guidelines, and Clinical Management Hypertensio...
Hypertension: New Concepts, Guidelines, and Clinical Management 	 Hypertensio...Hypertension: New Concepts, Guidelines, and Clinical Management 	 Hypertensio...
Hypertension: New Concepts, Guidelines, and Clinical Management Hypertensio...
MedicineAndFamily
 

Similar to AACVPR 2006 (20)

Obesity paradox
Obesity paradoxObesity paradox
Obesity paradox
 
07 abdominal obesity_and_association_with.1
07   abdominal obesity_and_association_with.107   abdominal obesity_and_association_with.1
07 abdominal obesity_and_association_with.1
 
07 abdominal obesity_and_association_with.1
07   abdominal obesity_and_association_with.107   abdominal obesity_and_association_with.1
07 abdominal obesity_and_association_with.1
 
Obesity and Cardiovascular Disease
Obesity and Cardiovascular Disease Obesity and Cardiovascular Disease
Obesity and Cardiovascular Disease
 
Abdominal Obesity or Visceral Adiposity In HIV patients
Abdominal Obesity or Visceral Adiposity In HIV patientsAbdominal Obesity or Visceral Adiposity In HIV patients
Abdominal Obesity or Visceral Adiposity In HIV patients
 
COMPARISON OF RISK FACTORS IN YOUNG ADULTS WITH OLDER ADULT PATIENTS WITH REC...
COMPARISON OF RISK FACTORS IN YOUNG ADULTS WITH OLDER ADULT PATIENTS WITH REC...COMPARISON OF RISK FACTORS IN YOUNG ADULTS WITH OLDER ADULT PATIENTS WITH REC...
COMPARISON OF RISK FACTORS IN YOUNG ADULTS WITH OLDER ADULT PATIENTS WITH REC...
 
Jennifer Tremmel - Sex Differences In Cardiovascular Disease
Jennifer Tremmel - Sex Differences In Cardiovascular DiseaseJennifer Tremmel - Sex Differences In Cardiovascular Disease
Jennifer Tremmel - Sex Differences In Cardiovascular Disease
 
How Should One Decide Whom to Treat for Hypertension? How Should One Decide...
How Should One Decide Whom to Treat for Hypertension? 	 How Should One Decide...How Should One Decide Whom to Treat for Hypertension? 	 How Should One Decide...
How Should One Decide Whom to Treat for Hypertension? How Should One Decide...
 
Lifestyle and chronic diseases - Dr.Ravi Andrews
Lifestyle and chronic diseases  - Dr.Ravi Andrews Lifestyle and chronic diseases  - Dr.Ravi Andrews
Lifestyle and chronic diseases - Dr.Ravi Andrews
 
Managing co morbidities of inflammatory arthritis
Managing co morbidities of inflammatory arthritisManaging co morbidities of inflammatory arthritis
Managing co morbidities of inflammatory arthritis
 
BODY FAT DEPOSITION AND RISK FACTORS OF CARDIOVASCULAR DISEASES IN MEN
BODY FAT DEPOSITION AND RISK FACTORS OF CARDIOVASCULAR DISEASES IN MENBODY FAT DEPOSITION AND RISK FACTORS OF CARDIOVASCULAR DISEASES IN MEN
BODY FAT DEPOSITION AND RISK FACTORS OF CARDIOVASCULAR DISEASES IN MEN
 
Obesity and heart disease
Obesity and heart diseaseObesity and heart disease
Obesity and heart disease
 
Diet, obesity, lifestyle and cancer prevention: epidemiologic perspectives
Diet, obesity, lifestyle and cancer prevention: epidemiologic perspectives Diet, obesity, lifestyle and cancer prevention: epidemiologic perspectives
Diet, obesity, lifestyle and cancer prevention: epidemiologic perspectives
 
Newsletter July07
Newsletter July07Newsletter July07
Newsletter July07
 
Riesgo Cardiovascular en el paciente VIH
Riesgo Cardiovascular en el paciente VIHRiesgo Cardiovascular en el paciente VIH
Riesgo Cardiovascular en el paciente VIH
 
Obesity and risk factor
Obesity and risk factorObesity and risk factor
Obesity and risk factor
 
AliceTang
AliceTangAliceTang
AliceTang
 
HIV and Nutrition Presentation
HIV and Nutrition PresentationHIV and Nutrition Presentation
HIV and Nutrition Presentation
 
Heart health for PLHIV: some directions
Heart health for PLHIV:  some directionsHeart health for PLHIV:  some directions
Heart health for PLHIV: some directions
 
Hypertension: New Concepts, Guidelines, and Clinical Management Hypertensio...
Hypertension: New Concepts, Guidelines, and Clinical Management 	 Hypertensio...Hypertension: New Concepts, Guidelines, and Clinical Management 	 Hypertensio...
Hypertension: New Concepts, Guidelines, and Clinical Management Hypertensio...
 

More from Robert Lowe

AHA NPAM EPI 2009 Abstract
AHA NPAM EPI 2009 AbstractAHA NPAM EPI 2009 Abstract
AHA NPAM EPI 2009 Abstract
Robert Lowe
 
AHA NPAM EPI 2007 Abstract
AHA NPAM EPI 2007 AbstractAHA NPAM EPI 2007 Abstract
AHA NPAM EPI 2007 Abstract
Robert Lowe
 
AACVPR 2002
AACVPR 2002AACVPR 2002
AACVPR 2002
Robert Lowe
 
NAASO October 2003
NAASO October 2003NAASO October 2003
NAASO October 2003
Robert Lowe
 
NAASO 2005 Power Point
NAASO 2005 Power PointNAASO 2005 Power Point
NAASO 2005 Power Point
Robert Lowe
 
NAASO 2007 Abstract 2
NAASO 2007 Abstract 2NAASO 2007 Abstract 2
NAASO 2007 Abstract 2
Robert Lowe
 
NAASO 2007 Abstract 1
NAASO 2007 Abstract 1NAASO 2007 Abstract 1
NAASO 2007 Abstract 1
Robert Lowe
 
NAASO 2006 Abstract
NAASO 2006 AbstractNAASO 2006 Abstract
NAASO 2006 Abstract
Robert Lowe
 
NAASO October 2006
NAASO October 2006NAASO October 2006
NAASO October 2006
Robert Lowe
 
ACSM 2005
ACSM 2005ACSM 2005
ACSM 2005
Robert Lowe
 
AACVPR 2002 Presentation
AACVPR 2002 PresentationAACVPR 2002 Presentation
AACVPR 2002 Presentation
Robert Lowe
 
AACVPR 2002
AACVPR 2002AACVPR 2002
AACVPR 2002
Robert Lowe
 
AACVPR 2003
AACVPR 2003AACVPR 2003
AACVPR 2003
Robert Lowe
 
AACVPR 2000
AACVPR 2000AACVPR 2000
AACVPR 2000
Robert Lowe
 

More from Robert Lowe (14)

AHA NPAM EPI 2009 Abstract
AHA NPAM EPI 2009 AbstractAHA NPAM EPI 2009 Abstract
AHA NPAM EPI 2009 Abstract
 
AHA NPAM EPI 2007 Abstract
AHA NPAM EPI 2007 AbstractAHA NPAM EPI 2007 Abstract
AHA NPAM EPI 2007 Abstract
 
AACVPR 2002
AACVPR 2002AACVPR 2002
AACVPR 2002
 
NAASO October 2003
NAASO October 2003NAASO October 2003
NAASO October 2003
 
NAASO 2005 Power Point
NAASO 2005 Power PointNAASO 2005 Power Point
NAASO 2005 Power Point
 
NAASO 2007 Abstract 2
NAASO 2007 Abstract 2NAASO 2007 Abstract 2
NAASO 2007 Abstract 2
 
NAASO 2007 Abstract 1
NAASO 2007 Abstract 1NAASO 2007 Abstract 1
NAASO 2007 Abstract 1
 
NAASO 2006 Abstract
NAASO 2006 AbstractNAASO 2006 Abstract
NAASO 2006 Abstract
 
NAASO October 2006
NAASO October 2006NAASO October 2006
NAASO October 2006
 
ACSM 2005
ACSM 2005ACSM 2005
ACSM 2005
 
AACVPR 2002 Presentation
AACVPR 2002 PresentationAACVPR 2002 Presentation
AACVPR 2002 Presentation
 
AACVPR 2002
AACVPR 2002AACVPR 2002
AACVPR 2002
 
AACVPR 2003
AACVPR 2003AACVPR 2003
AACVPR 2003
 
AACVPR 2000
AACVPR 2000AACVPR 2000
AACVPR 2000
 

Recently uploaded

CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
rishi2789
 
vonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentationvonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentation
Dr.pavithra Anandan
 
OCT Training Course for clinical practice Part 1
OCT Training Course for clinical practice Part 1OCT Training Course for clinical practice Part 1
OCT Training Course for clinical practice Part 1
KafrELShiekh University
 
Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)
Josep Vidal-Alaball
 
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptxMuscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
Top Effective Soaps for Fungal Skin Infections in India
Top Effective Soaps for Fungal Skin Infections in IndiaTop Effective Soaps for Fungal Skin Infections in India
Top Effective Soaps for Fungal Skin Infections in India
SwisschemDerma
 
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptxVestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
Osteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdfOsteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdf
Jim Jacob Roy
 
Histololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptxHistololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptx
AyeshaZaid1
 
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptxREGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
LaniyaNasrink
 
Ketone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistryKetone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistry
Dhayanithi C
 
Aortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 BernAortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 Bern
suvadeepdas911
 
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdfCHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
rishi2789
 
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachIntegrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Ayurveda ForAll
 
Diabetic nephropathy diagnosis treatment
Diabetic nephropathy diagnosis treatmentDiabetic nephropathy diagnosis treatment
Diabetic nephropathy diagnosis treatment
arahmanzai5
 
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
19various
 
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxDoes Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
walterHu5
 
Cell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune DiseaseCell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune Disease
Health Advances
 
Histopathology of Rheumatoid Arthritis: Visual treat
Histopathology of Rheumatoid Arthritis: Visual treatHistopathology of Rheumatoid Arthritis: Visual treat
Histopathology of Rheumatoid Arthritis: Visual treat
DIVYANSHU740006
 
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
rishi2789
 

Recently uploaded (20)

CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
 
vonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentationvonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentation
 
OCT Training Course for clinical practice Part 1
OCT Training Course for clinical practice Part 1OCT Training Course for clinical practice Part 1
OCT Training Course for clinical practice Part 1
 
Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)
 
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptxMuscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
 
Top Effective Soaps for Fungal Skin Infections in India
Top Effective Soaps for Fungal Skin Infections in IndiaTop Effective Soaps for Fungal Skin Infections in India
Top Effective Soaps for Fungal Skin Infections in India
 
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptxVestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
 
Osteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdfOsteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdf
 
Histololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptxHistololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptx
 
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptxREGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
 
Ketone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistryKetone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistry
 
Aortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 BernAortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 Bern
 
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdfCHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
 
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachIntegrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
 
Diabetic nephropathy diagnosis treatment
Diabetic nephropathy diagnosis treatmentDiabetic nephropathy diagnosis treatment
Diabetic nephropathy diagnosis treatment
 
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
 
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxDoes Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
 
Cell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune DiseaseCell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune Disease
 
Histopathology of Rheumatoid Arthritis: Visual treat
Histopathology of Rheumatoid Arthritis: Visual treatHistopathology of Rheumatoid Arthritis: Visual treat
Histopathology of Rheumatoid Arthritis: Visual treat
 
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
 

AACVPR 2006

  • 1. WAIST-TO-TALLNESS RATIO AS A MARKER OF CARDIOVASCULAR DISEASE RISK IN PRIMARY PREVENTION. ABCs of Health Robert C. Lowe, MA1, Debbie Zimmerman, MBA1, and Philip Chen, MD, PhD2 1Polk County School Board, Winter Haven, Florida and 2Cognoscenti Health Institute, Orlando, Florida. Introduction Results Recent research has suggested that Waist-To-Tallness Ratio (WTR) has greater There were no significant differences between males and females for AGE, SMOKE, or PA - specificity and sensitivity for overall-cardiovascular disease (CVD) risk than either (P > 0.05). Females were more likely to have a family history of CVD and DM (P < 0.05). body mass index (BMI) or waist circumference (WC). Schneider, et al. (2005) recently Both male and female WC (100.6 ± 14 cm and 86.2 ± 16 cm, respectively) was below reported a cut-off value for WTR of 0.53 for women and 0.55 for men. current cut-points. Females had increased %BF compared to males (35.2 ± 7% vs. 27.0 ± 7%). Males had greater BMI (30.2 ± 7 vs. 29.0 ± 5), SBP (131 ± 15 mmHg vs. 124 ± 17 mmHg) and DBP (83 ± 10 mmHg vs. 79 ± 10 mmHg) compared to females (all P < 0.05). Male WTR (0.57; P < 0.05) was greater than cut-point and female WTR (0.53; P = Purpose 0.37) equaled cut point To determine whether WTR is a useful marker of CVD risk in primary prevention. Table 1. Bivariate correlations between Waist to Height Ratio and selected variables. Heart Smoking Disease Diabetes Physical Systolic Diastolic Body Age Gender History History History Activity Weight BP BP Fat BMI Pearson Methods Correlation 0.19** 0.14** 0.06 0.06 0.09** -0.13** 0.81** 0.37** 0.31** 0.64** 0.88** p value 0.000 0.000 0.060 0.069 0.007 0.000 0.000 0.000 0.000 0.000 0.000 subjects 887 887 885 875 862 877 887 884 881 613 872 Adults (n = 887; AGE = 46.6 ± 11yrs) completed a smoking (SMOKE), heart disease (CVD), diabetes (DM) and physical activity (PA) survey at a wellness screening. Height, weight, WC, systolic blood pressure (SBP), diastolic blood pressure (DBP), and **Correlation is significant at the 0.01 level (2-tailed) percent body fat (%BF) were measured; BMI and WTR were calculated. Differences between genders for CVD risk were explored by one-way ANOVA; differences between gender cut-points and WTR were compared by one sample t-test; significance was set Conclusions at P < 0.05.. Both males and females were at increased risk for CVD based on WTR cut-points suggested by Schneider, et al. (2005) despite WC being below current cut-points. The greater WTR cut-point in males was associated with increased BMI, SBP, and DBP compared to females. These results suggest WTR alone may not adequately predict overall CVD risk in adults. In addition, it may be For further information please contact: useful to consider gender differences when designing primary prevention interventions to Robert Lowe, M.A., FAACVPR reduce overall risk for CVD. robert.lowe@polk-fl.net